Boston, MA 06/05/2014 (wallstreetpr) – ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), which is said to be a market leader of antisense therapeutics, on June 4, 2014 announced that the ISIS Pharmaceuticals’ management will present the overview of the company at the Goldman Sachs 35th Annual Global Healthcare Conference. This will take place on June 11, 2014 at 8:40 a.m. PT in Rancho Palos Verdes, CA.
Live Webcast of the Company Overview to Investors & Media
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) also announced that there would be a live webcast of the presentation, especially meant for Investors & Media section of www.isispharm.com, the official website of the company. There will be the availability of replay on the website within 48 hours, and it will also be accessible through archive for a limited period.
In a similar move, Hologic, Inc. (NASDAQ:HOLX) also made an announcement of the company’s overview presentation by the President and Chief Executive Officer, Stephen MacMillan.
About The Goldman Sachs 35th Annual Global Healthcare Conference
The Goldman Sachs 35th Annual Global Healthcare Conference will begin on June 10, 2014 and will continue till June 12, 2014. The conference is scheduled to take place in Rancho Palos Verdes, CA, U.S.
About ISIS Pharmaceuticals
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) has remained focused in reinforcing its position in technology involving antisense, in order to develop and discover new drugs for its own product pipeline as well as partners. At present, the company has a broad pipeline of 32 drugs which are used for the treatment of various diseases such as metabolic, cardiovascular and rare diseases like cancers and neurological disorders. The patents of the company facilitate extensive and strong protection for the technology as well as drugs of ISIS. The partner of ISIS- Genzyme is responsible for commercialisation of KYNAMRO®, the leading product of the company, in the U.S. markets as well as other markets for the treatment of homozygous FH’s patients.
